Clinical Trials Logo
NCT number NCT01000727
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 3
Start date December 2009
Completion date April 2014

Clinical Trial Summary

This study will test whether darapladib can safely lower the chances of having a cardiovascular event (such as a heart attack or urgent coronary revascularization (e.g. medical procedures performed to restore the normal blood flow in patients with atherosclerosis)) when treatment is started within 30 days after an acute coronary syndrome (also called ACS).


Clinical Trial Description

Subjects who qualify for the study will be randomized 1:1 to either darapladib or placebo administered in addition to standard therapy. Following the baseline visit, subjects will be expected to return for clinic visits at 1 month, 3 months, 6 months and every 6 months until the end of the study.


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


See also
Status Clinical Trial Phase
 Recruiting NCT02944123 - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR) Phase 3
 Recruiting NCT02892903 - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment - at the Time of Coronary Angiography - Affect Management Strategy, Hospital Costs and Outcomes? Phase 3
 Recruiting NCT02935088 - PRESSUREwire Study N/A
 Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
 Recruiting NCT02620202 - Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain N/A
 Recruiting NCT02673437 - Rivaroxaban ACS Specialist Cohort Event Monitoring Study N/A
 Recruiting NCT02533128 - Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery N/A
 Active, not recruiting NCT02922140 - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit N/A
 Not yet recruiting NCT02536677 - The Evaluation and Management of Patients With Acute Chest Pain in China N/A
 Not yet recruiting NCT02508714 - Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents Phase 4
 Recruiting NCT02044146 - A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk Phase 2/Phase 3
 Active, not recruiting NCT02374775 - Exploring the Mechanism of the Plaque Rupture in Acute Myocardial Infarction N/A
 Active, not recruiting NCT02887066 - Observatory on Emergency Care for Acute Coronary Syndrome in Grand Est of France N/A
 Recruiting NCT01931852 - Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin Phase 3
 Recruiting NCT01826994 - Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome N/A
 Active, not recruiting NCT01959451 - Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial Phase 4
 Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
 Active, not recruiting NCT01665521 - Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain Phase 3
 Completed NCT01642966 - Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Phase 4
 Completed NCT01609647 - Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention Phase 3